Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Dow
Moodys
Medtronic
Merck

Last Updated: January 25, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for Myrcludex B


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Myrcludex B?

Myrcludex B is an investigational drug.

There have been 6 clinical trials for Myrcludex B. The most recent clinical trial was a Phase 2 trial, which was initiated on April 17th 2019.

The most common disease conditions in clinical trials are Hepatitis A, Hepatitis, and Hepatitis, Chronic. The leading clinical trial sponsors are Hepatera Ltd., Gilead Sciences, and MYR GmbH.

There are two US patents protecting this investigational drug and twenty-seven international patents.

Recent Clinical Trials for Myrcludex B
TitleSponsorPhase
Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD)Hepatera Ltd.Phase 2
Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD)Gilead SciencesPhase 2
Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD)MYR GmbHPhase 2

See all Myrcludex B clinical trials

Clinical Trial Summary for Myrcludex B

Top disease conditions for Myrcludex B
Top clinical trial sponsors for Myrcludex B

See all Myrcludex B clinical trials

US Patents for Myrcludex B

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Myrcludex B ⤷  Try it Free Non-invasive method for assessing liver fibrosis progression CENTRE HOSPITALIER UNIVERSITAIRE D'ANGERS (Angers, FR) UNIVERSITE D'ANGERS (Angers, FR) ⤷  Try it Free
Myrcludex B ⤷  Try it Free Oligonucleotide chelate complex--polypeptide compositions and methods REPLICOR INC. (Montreal, CA) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Myrcludex B

Drugname Country Document Number Estimated Expiration Related US Patent
Myrcludex B Australia AU2013262416 2032-05-18 ⤷  Try it Free
Myrcludex B Brazil BR112014028654 2032-05-18 ⤷  Try it Free
Myrcludex B Canada CA2873529 2032-05-18 ⤷  Try it Free
Myrcludex B Chile CL2014003134 2032-05-18 ⤷  Try it Free
Myrcludex B China CN104349793 2032-05-18 ⤷  Try it Free
Myrcludex B Colombia CO7131387 2032-05-18 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Dow
Moodys
Medtronic
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.